17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The tau positron emission tomography (PET) ligand 18F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain.

          Methods

          We performed 18F-flortaucipir imaging in patients with the FTD syndromes ( n = 45): nonfluent variant primary progressive aphasia (nfvPPA) ( n = 11), corticobasal syndrome (CBS) ( n = 10), behavioral variant frontotemporal dementia (bvFTD) ( n = 10), semantic variant primary progressive aphasia (svPPA) ( n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau ( MAPT) ( n = 6), chromosome 9 open reading frame 72 ( C9ORF72) ( n = 5), and progranulin ( GRN) ( n = 1). All patients underwent MRI and β-amyloid biomarker testing via 11C-PiB or cerebrospinal fluid. 18F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches.

          Results

          On qualitative assessment, patients with nfvPPA showed elevated 18F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated 18F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer’s-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild 18F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology.

          Conclusions

          18F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed.

          Electronic supplementary material

          The online version of this article (10.1186/s13195-019-0470-7) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references77

          • Record: found
          • Abstract: found
          • Article: not found

          The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

          Next-generation DNA sequencing (NGS) projects, such as the 1000 Genomes Project, are already revolutionizing our understanding of genetic variation among individuals. However, the massive data sets generated by NGS--the 1000 Genome pilot alone includes nearly five terabases--make writing feature-rich, efficient, and robust analysis tools difficult for even computationally sophisticated individuals. Indeed, many professionals are limited in the scope and the ease with which they can answer scientific questions by the complexity of accessing and manipulating the data produced by these machines. Here, we discuss our Genome Analysis Toolkit (GATK), a structured programming framework designed to ease the development of efficient and robust analysis tools for next-generation DNA sequencers using the functional programming philosophy of MapReduce. The GATK provides a small but rich set of data access patterns that encompass the majority of analysis tool needs. Separating specific analysis calculations from common data management infrastructure enables us to optimize the GATK framework for correctness, stability, and CPU and memory efficiency and to enable distributed and shared memory parallelization. We highlight the capabilities of the GATK by describing the implementation and application of robust, scale-tolerant tools like coverage calculators and single nucleotide polymorphism (SNP) calling. We conclude that the GATK programming framework enables developers and analysts to quickly and easily write efficient and robust NGS tools, many of which have already been incorporated into large-scale sequencing projects like the 1000 Genomes Project and The Cancer Genome Atlas.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.

            In this study, we have assessed the validity and reliability of an automated labeling system that we have developed for subdividing the human cerebral cortex on magnetic resonance images into gyral based regions of interest (ROIs). Using a dataset of 40 MRI scans we manually identified 34 cortical ROIs in each of the individual hemispheres. This information was then encoded in the form of an atlas that was utilized to automatically label ROIs. To examine the validity, as well as the intra- and inter-rater reliability of the automated system, we used both intraclass correlation coefficients (ICC), and a new method known as mean distance maps, to assess the degree of mismatch between the manual and the automated sets of ROIs. When compared with the manual ROIs, the automated ROIs were highly accurate, with an average ICC of 0.835 across all of the ROIs, and a mean distance error of less than 1 mm. Intra- and inter-rater comparisons yielded little to no difference between the sets of ROIs. These findings suggest that the automated method we have developed for subdividing the human cerebral cortex into standard gyral-based neuroanatomical regions is both anatomically valid and reliable. This method may be useful for both morphometric and functional studies of the cerebral cortex as well as for clinical investigations aimed at tracking the evolution of disease-induced changes over time, including clinical trials in which MRI-based measures are used to examine response to treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

              Based on the recent literature and collective experience, an international consortium developed revised guidelines for the diagnosis of behavioural variant frontotemporal dementia. The validation process retrospectively reviewed clinical records and compared the sensitivity of proposed and earlier criteria in a multi-site sample of patients with pathologically verified frontotemporal lobar degeneration. According to the revised criteria, 'possible' behavioural variant frontotemporal dementia requires three of six clinically discriminating features (disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/compulsive behaviours, hyperorality and dysexecutive neuropsychological profile). 'Probable' behavioural variant frontotemporal dementia adds functional disability and characteristic neuroimaging, while behavioural variant frontotemporal dementia 'with definite frontotemporal lobar degeneration' requires histopathological confirmation or a pathogenic mutation. Sixteen brain banks contributed cases meeting histopathological criteria for frontotemporal lobar degeneration and a clinical diagnosis of behavioural variant frontotemporal dementia, Alzheimer's disease, dementia with Lewy bodies or vascular dementia at presentation. Cases with predominant primary progressive aphasia or extra-pyramidal syndromes were excluded. In these autopsy-confirmed cases, an experienced neurologist or psychiatrist ascertained clinical features necessary for making a diagnosis according to previous and proposed criteria at presentation. Of 137 cases where features were available for both proposed and previously established criteria, 118 (86%) met 'possible' criteria, and 104 (76%) met criteria for 'probable' behavioural variant frontotemporal dementia. In contrast, 72 cases (53%) met previously established criteria for the syndrome (P < 0.001 for comparison with 'possible' and 'probable' criteria). Patients who failed to meet revised criteria were significantly older and most had atypical presentations with marked memory impairment. In conclusion, the revised criteria for behavioural variant frontotemporal dementia improve diagnostic accuracy compared with previously established criteria in a sample with known frontotemporal lobar degeneration. Greater sensitivity of the proposed criteria may reflect the optimized diagnostic features, less restrictive exclusion features and a flexible structure that accommodates different initial clinical presentations. Future studies will be needed to establish the reliability and specificity of these revised diagnostic guidelines.
                Bookmark

                Author and article information

                Contributors
                Richard.Tsai@ucsf.edu
                Bejanin.cyceron@gmail.com
                Orit.LesmanSegev@ucsf.edu
                Renaud.LaJoie@ucsf.edu
                Adrienne.Visani@ucsf.edu
                Viktoriya.Bourakova@ucsf.edu
                JPOneil@lbl.gov
                MJanabi@lbl.gov
                slbaker@lbl.gov
                suzee.lee@ucsf.edu
                david.perry@ucsf.edu
                Lynn.Bajorek@ucsf.edu
                anna.karydas@ucsf.edu
                Salvatore.spina@ucsf.edu
                lea.grinberg@ucsf.edu
                bill.seeley@ucsf.edu
                edasilvaramos@mednet.ucla.edu
                gcoppola@ucla.edu
                MariaLuisa.GornoTempini@ucsf.edu
                Bruce.Miller@ucsf.edu
                Howie.Rosen@ucsf.edu
                jagust@berkeley.edu
                adam.boxer@ucsf.edu
                Gil.Rabinovici@ucsf.edu
                Journal
                Alzheimers Res Ther
                Alzheimers Res Ther
                Alzheimer's Research & Therapy
                BioMed Central (London )
                1758-9193
                31 January 2019
                31 January 2019
                2019
                : 11
                : 13
                Affiliations
                [1 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Memory and Aging Center, , University of California at San Francisco, ; 675 Nelson Rising Lane, Suite 190, San Francisco, CA USA
                [2 ]ISNI 0000 0001 2181 7878, GRID grid.47840.3f, Helen Wills Neuroscience Institute, , University of California at Berkeley, ; Berkeley, USA
                [3 ]ISNI 0000 0001 2231 4551, GRID grid.184769.5, Life Sciences Division, Lawrence Berkeley National Laboratory, ; Berkeley, USA
                [4 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, , University of California, ; Los Angeles, CA USA
                Author information
                http://orcid.org/0000-0003-2784-7992
                Article
                470
                10.1186/s13195-019-0470-7
                6357510
                30704514
                0bd1a1a6-1ee7-4cc8-8fae-0a1736ddf321
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 2 July 2018
                : 17 January 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000049, National Institute on Aging;
                Award ID: K23AG055688
                Award ID: K23AG045289
                Award ID: K08AG052648
                Award ID: K24AG053435
                Award ID: P01AG019724
                Award ID: U01 AG052943
                Award ID: P50-AG023501
                Award ID: P50-AG023501
                Award ID: R01AG034570
                Award ID: R01AG038791
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000065, National Institute of Neurological Disorders and Stroke;
                Award ID: R01NS050915
                Award ID: U54NS092089
                Award ID: U54NS092089
                Award ID: U54NS092089
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000055, National Institute on Deafness and Other Communication Disorders;
                Award ID: K24DC015544
                Award Recipient :
                Funded by: Tau Consortium
                Funded by: FundRef http://dx.doi.org/10.13039/100000864, Michael J. Fox Foundation for Parkinson's Research;
                Funded by: FundRef http://dx.doi.org/10.13039/100003607, Association for Frontotemporal Degeneration;
                Funded by: Bluefield Project to Cure FTD
                Funded by: Consortium for Frontotemporal Dementia Research
                Funded by: State of California DHS Alzheimer's Disease Research Center of California
                Award ID: 04-33516
                Funded by: State of California DHS Alzheimer’s Disease Research Center of California
                Award ID: DHS04-33516
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100002915, Fondation pour la Recherche Médicale;
                Funded by: FundRef http://dx.doi.org/10.13039/100000957, Alzheimer's Association;
                Award ID: AARF-16-443577
                Award Recipient :
                Funded by: UCSF PPG
                Funded by: UCSF-ADRC
                Funded by: John Douglas French Alzheimer's Foundation
                Categories
                Research
                Custom metadata
                © The Author(s) 2019

                Neurology
                biomarkers,frontotemporal dementia,tau imaging,neuropathology,tau
                Neurology
                biomarkers, frontotemporal dementia, tau imaging, neuropathology, tau

                Comments

                Comment on this article